KPTIThe 0.89 level seems to function as support and could be a good basis to head towards the upper resistances, 1.17-1.40, 1.6 otherwise the collapse of this level towards new lows
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.6718 EUR
−129.65 M EUR
132.31 M EUR
115.36 M
About Karyopharm Therapeutics Inc.
Sector
CEO
Richard A. Paulson
Headquarters
Newton
Website
Founded
2008
FIGI
BBG00645T1K4
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
KPTIthe support in area 092 holds and from here it seems to bounce towards the resistance in area 1.2 and then 1.4; otherwise the failure of the 092 area support would lead to a bearish scenario
$KPTI: Low risk buy signalNice setup in $KPTI, I suggest buying these names with small positions considering the volatility that can occur after catalysts when new data is released, or around FDA approvals, etc.
Upside can be substantial though, so if technicals and fundamentals align, it's worth keeping some exposure.
Best
KPTI - Falling WedgeFalling wedge idea for KPTI.
Areas above the arrows up are very similar hence I propose a breakout of the falling wedge is coming.
Falling wedges are considered a bullish pattern.
Bearish Bearish Divergence on the 1 hr chart. I am selling short here. Quick trade, as it is the 1 hr after all.
KPTI | LongNASDAQ:KPTI
Possible Scenario: Long
Evidence: Price Action, IH&S, Money-Flow
TP1: 7.85$
Call options, 01/21/2022, Strike 7.5$
*This is my idea and could be wrong 100%
$KPTI Target PTs 18-29 and higherAntengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma
SHANGHAI and HONG KONG, April 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicate
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
KPTI4906769
Karyopharm Therapeutics Inc 3.0% 15-OCT-2025Yield to maturity
30.27%
Maturity date
Oct 15, 2025
KPTI5813817
Karyopharm Therapeutics Inc 6.0% 13-MAY-2029Yield to maturity
15.52%
Maturity date
May 13, 2029
Explore more bonds
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange KARYOPHARM THERAP.DL-0001 stocks are traded under the ticker 25K.
We've gathered analysts' opinions on KARYOPHARM THERAP.DL-0001 future price: according to them, 25K price has a max estimate of 6.41 EUR and a min estimate of 1.83 EUR. Watch 25K chart and read a more detailed KARYOPHARM THERAP.DL-0001 stock forecast: see what analysts think of KARYOPHARM THERAP.DL-0001 and suggest that you do with its stocks.
Yes, you can track KARYOPHARM THERAP.DL-0001 financials in yearly and quarterly reports right on TradingView.
KARYOPHARM THERAP.DL-0001 is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
25K earnings for the last quarter are −0.23 EUR per share, whereas the estimation was −0.24 EUR resulting in a 1.09% surprise. The estimated earnings for the next quarter are −0.24 EUR per share. See more details about KARYOPHARM THERAP.DL-0001 earnings.
KARYOPHARM THERAP.DL-0001 revenue for the last quarter amounts to 34.83 M EUR, despite the estimated figure of 34.06 M EUR. In the next quarter, revenue is expected to reach 36.74 M EUR.
25K net income for the last quarter is −28.81 M EUR, while the quarter before that showed 22.21 M EUR of net income which accounts for −229.68% change. Track more KARYOPHARM THERAP.DL-0001 financial stats to get the full picture.
No, 25K doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 325.00 employees. See our rating of the largest employees — is KARYOPHARM THERAP.DL-0001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KARYOPHARM THERAP.DL-0001 EBITDA is −112.84 M EUR, and current EBITDA margin is −88.34%. See more stats in KARYOPHARM THERAP.DL-0001 financial statements.
Like other stocks, 25K shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KARYOPHARM THERAP.DL-0001 stock right from TradingView charts — choose your broker and connect to your account.